DRTG(SH:600329) Shang Hai Zheng Quan Bao·2025-08-25 21:33Core Viewpoint - The company is committed to high-quality development and enhancing shareholder returns through the implementation of the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan for 2024 and 2025 [12] Group 1: Focus on Core Business - The company continues to concentrate resources on the traditional Chinese medicine sector, achieving a main industrial revenue of 2.645 billion yuan in the first half of 2025, a year-on-year increase of 0.87% [1] - Sales of the "Suxiao Jiuxin Wan" reached 1.128 billion yuan, up 5.45%, while "Qingyan Diban" sales surged by 52.28% to 289 million yuan [1] Group 2: Enhancing New Quality Productivity - The company has implemented unified internal control standards for medicinal materials, establishing 46 procurement standards that exceed the Chinese Pharmacopoeia [3] - The company has initiated the drafting of the "Tianyao Darentang Medicinal Material Quality Standards (2025)" and completed initial drafts for 100 varieties [3] - The company has launched several innovative products and completed various quality stability studies, including the successful entry of "Suxiao Jiuxin Wan" into a modern Chinese medicine technology innovation project [3] Group 3: Shareholder Returns - The company distributed a cash dividend of 1.28 yuan per 10 shares in July 2024, totaling 986 million yuan, and plans to implement the same dividend in July 2025 [4] - Since its listing in 2001, the company has distributed a total of 5.117 billion yuan in cash dividends, with an average dividend payout ratio of 50.69% [4] Group 4: Investor Communication and Transparency - The company has improved the readability of its announcements and actively engages in various investor communication activities, receiving an A-level rating for information disclosure in 2023-2024 [6] - The company has organized events for investors to experience its culture and products, enhancing shareholder engagement [6] Group 5: Governance and Compliance - The company is committed to updating internal regulations and enhancing investor protection, particularly for minority shareholders [8] - The company has established a special management approach for excess incentives to align the interests of key personnel with those of shareholders [9]